Navigation Links
Gene Discovered by Researchers Tied to Pancreatic Cancer

A gene discovered by researchers at the University of North Carolina at Chapel Hill School of Medicine has been associated with two forms of pancreatic cancer//, according to a study by an international group of researchers.

The gene, called palladin, was discovered six years ago by Dr. Carol Otey and her former student, Dr. Mana Parast, now a pathology fellow with Brigham and Women’s Hospital in Boston. Otey has shown that palladin is involved in the formation of scar tissue on nerve cells in the brain or spinal cord, and it’s found in cells that are moving, including embryonic cells and cells at the edge of wounds.

“Now we find it implicated in pancreatic cancer,” said Otey, an associate professor of cell and molecular physiology at UNC and a member of the UNC Neuroscience Center.

A study reported in the Dec. 12 issue of PLOS-Medicine, led by scientists at the University of Washington and the University of Pittsburgh, found pallidan overexpressed in people with sporadic, or non-familial, pancreatic cancer. A mutation of the gene was overexpressed in cells of people with familial pancreatic cancer, which makes up at least 10 percent of all pancreatic cancer cases. Otey is a co-author on the paper.

This discovery could lead to earlier diagnosis and more targeted treatments. In the United States, pancreatic cancer is the fourth leading cause of cancer death and the third leading cause of cancer death among people 40 to 59 years. Most people with the disease die within a year of diagnosis; about 95 percent of patients die within five years.

Palladin, which Otey named for 16th century architect Andrea Palladio, “is very involved in the architecture of cells, specifically via the actin cytoskeleton, a polymer protein complex that provides much of the basis for cell shape,” Otey said.

In 1996 Dr. Teresa A. Brentnall, an associate professor of medicine at the University of Washington, became aware of
'"/>




Page: 1 2

Related medicine news :

1. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
2. Origin Of SARS Virus Discovered
3. Another Cause of Thyroid Cancer Discovered
4. Details Of Heart Failure Discovered
5. Genes to Extend Longevity Discovered
6. Genetic Cause For Farsightedness Discovered
7. New Treatment Discovered For Pediatric Cholera
8. Molecule Behind Multiple Sclerosis Discovered
9. A Possible Cause Of Prostate Cancer Discovered
10. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
11. Prostate Cancer Stem Cells Discovered By York Researchers
Post Your Comments:
(Date:8/8/2008)... 8 /PRNewswire-FirstCall/ -- Hanger Orthopedic,Gro... Moody,s Investors,Service revised its outlook for..."stable." Moody,s also affirmed Hanger,s corporate...ith the outlook change from Moody,s as it reflects...," remarked George McHenry,Hanger,s Chief Financi...
(Date:8/7/2008)...terone may be a key factor in spreading disease am...uld help explain why males in a population are oft...se., , Previous research has linked testosteron...ion. Studies have shown that males, compared to fe...nt for a larger share of disease transmission. How...
(Date:8/7/2008)...Engineering Initiative Marks 12th Year of Summer ...GH, Aug. 7 /PRNewswire/ -- Twenty-four undergradua...ily across southwestern Pennsylvania,and the Pitts...ummer,Internship Program of the Pittsburgh Tissue ...gram is to expose greatly increased numbers of our...
(Date:8/7/2008)... /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE:,...AT study show that,once-daily EPZICOM (abacavir + ...aily Truvada(R) (tenofovir DF + emtricitabine) as ...data were presented today at the 17th,Internationa...s the first large, prospective, long-term, head-to...
Breaking Medicine News(10 mins):Health News:Testosterone key to disease transmission 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 2Health News:Thirty-seven College Students Participate in Regenerative Medicine Summer Research Program 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 2Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 3Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 4Health News:Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients 5
...he first published report of the HIV eradication p...ual on highly active antiretroviral therapy (HAART...lising this method. Currently available anti-HI...undetectable' levels in the blood, but they cannot...
...esearchers in the United States have identified th...is B virus (HBV) as a result of dental surgery, de...ng been followed. The case report has been publi...ases and the authors of both the paper and an acco...
...hose who knew Brodie Campbell are still in shock a...chool officials have reportedly brought in grief c...Brodie Campbell, who was a popular student at his ...y School in Coquitlam, British Columbia. The Fra...
...yron Perkins of Kentucky in US had made headlines ...er being released from prison in order to donate a...ured, along with his girlfriend Leen Ann Howard, a... in Puerto Vallarta on Mexico's Pacific coast, sai...
Other Medicine News:Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 2Health News:HIV Eradication Unlikely Following Bone Marrow Transplantation 3Health News:Despite Control Efforts HBV Found to Transmit After Dental Surgery 2Health News:Fugitive Who Ditched His Ailing Son Arrested After a Year 2
(Date:8/5/2008)...on-Whites New to Antiretroviral Therapy Respond ...EXICO CITY, Aug. 5 /- Initi...ce-daily dosing of Abbott,s (NYSE:,ABT) protease i...rovided,similar results for controlling the virus ...mmune system (increasing CD4 cells) in women compa...
(Date:8/5/2008)... 5 /- Tolerx, Inc., a,biopharmaceutic...t of novel,therapies for the treatment of immune-m...a collaborator, has moved a modified version of TR...to a phase 1 clinical trial,that has begun enrolli...safety and tolerability of both single and multipl...
(Date:8/5/2008)... /PRNewswire/-- Cara Therapeutics, Inc. today,anno...ts second-generation,peripherally acting kappa op...atment of acute and chronic pain. The drug candida...nfusion, and resulted in plasma levels of,CR845 ex...tivity. In,addition, CR845 infusion triggered a qu...
(Date:8/5/2008)...., Aug. 5 /- MicroDose Technologies,I...nical milestone in its,collaboration with Merck & ...ieved, triggering the first payment under the glob...haler (DPI) technology announced in March,2008. Th...Phase I clinical,study of an investigational compo...
Breaking Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845 2MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc. 2INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 14608 1INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 14608 2INCF and Allen Institute for Brain Science collaborate on Brain Atlas service improvement 14608 3Research promising for cystic fibrosis 14603 1Research promising for cystic fibrosis 14603 2New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies 14598 1New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies 14598 2New Healthcare Study Outlines Strategies to Increase Adoption of Home Health Monitoring Technologies 14598 3New study changes conditions for Spanish brown bears 2538 1New study changes conditions for Spanish brown bears 2538 2
...d,for the rapid, qualitative detection of Group ...at specimens. The kit is,self-contained and feat...m 25 or 50 tests including the throat swabs,and ...the rapid, qualitative detection of Group A Strept...
LH Ovulation Urine Test
AimStep Ovulation
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening.
Medicine Products: